{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:33:19Z","timestamp":1789788799460,"version":"4.0.1"},"reference-count":25,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Tralokinumab is an anti-IL-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD). While pivotal trials have demonstrated its efficacy, real-world data remain limited. Methods: We conducted a retrospective, multi-center study in the Basque Country including 109 adults with moderate-to-severe AD treated with tralokinumab. Clinical outcomes (EASI, IGA, BSA, DLQI, and NRS-pruritus\/sleep) were assessed at baseline, weeks 16, 24, and 52. Results: EASI-75\/90\/100 responses were 66%\/44%\/16% at week 16 and increased to 83%\/70%\/34% at week 52. Pruritus NRS decreased from 7.1 to 3.1 and DLQI from 17.8 to 9.0. Adverse events were uncommon, with only three cases of conjunctivitis (two discontinued). Conclusions: Our findings support tralokinumab as a safe and effective long-term therapy for AD in routine practice. Results were consistent with, or superior to, pivotal and other RWE studies.<\/jats:p>","DOI":"10.3390\/jcm14165727","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:30:38Z","timestamp":1755091838000},"page":"5727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Clinical Practice Evaluation of Tralokinumab in Atopic Dermatitis: A 52-Week Multi-Center Retrospective Study in the Basque Country"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6395","authenticated-orcid":false,"given":"Rosa Mar\u00eda","family":"Izu Belloso","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital Universitario Basurto, 48013 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Juli\u00e1 Manresa","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Basurto, 48013 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7641-6014","authenticated-orcid":false,"given":"Nekane","family":"Mart\u00ednez Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Basurto, 48013 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-3378","authenticated-orcid":false,"given":"Maider","family":"Pretel Irazabal","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Galdakao, 48960 Galdakao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-9486","authenticated-orcid":false,"given":"Vanesa","family":"Fatsini Blanch","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Araba, 01009 Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Ormaechea P\u00e9rez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Donostia, 20014 Donostia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-2039","authenticated-orcid":false,"given":"Manuel","family":"Pascual Ares","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Cruces, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-7547","authenticated-orcid":false,"given":"Juan Antonio","family":"Rat\u00f3n Nieto","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Cruces, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicenter, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.anai.2018.12.003","article-title":"The role of the skin microbiome in atopic dermatitis","volume":"122","author":"Nakatsuji","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: A randomized, double-blind, multicenter, placebo-controlled phase III trial (ECZTRA 3)","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","article-title":"Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/ced\/llad153","article-title":"Treatment of severe atopic dermatitis with tralokinumab in clinical practice: Short-term effectiveness and safety results","volume":"48","author":"Herranz","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14712598.2023.2292627","article-title":"Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: Results from a multicentric, multinational, retrospective, cohort study","volume":"23","author":"Chiricozzi","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s13555-025-01445-8","article-title":"Real-World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study","volume":"15","author":"Rodriguez","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40257-025-00927-x","article-title":"Real-world evidence of tralokinumab effectiveness and safety: A systematic review and meta-analysis","volume":"26","author":"Bunick","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","first-page":"E644","article-title":"Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study","volume":"37","author":"Pezzolo","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ced\/llad038","article-title":"Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice","volume":"48","author":"Shareef","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40261-023-01258-7","article-title":"Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study","volume":"43","author":"Ghislain","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"adv42275","DOI":"10.2340\/actadv.v105.42275","article-title":"Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results from a Real-world Multicentre Study","volume":"105","author":"Calabrese","year":"2025","journal-title":"Acta Dermato-Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2216815","DOI":"10.1080\/09546634.2023.2216815","article-title":"Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: A real-life 16-week experience","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_18","first-page":"E11","article-title":"Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study","volume":"38","author":"Pezzolo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/derm.2023.0030","article-title":"First Short-Term Effectiveness and Security Data of Tralokinumab in Severe Atopic Dermatitis\u00ae in Real Clinical Practice","volume":"35","author":"Castro","year":"2024","journal-title":"Dermatitis\u00ae"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/cea.14461","article-title":"Ocular surface disease in moderate to severe atopic dermatitis patients and the effect of biological therapy","volume":"54","author":"Achten","year":"2024","journal-title":"Clin. Exp. Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2023.01.043","article-title":"Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review","volume":"89","author":"Shi","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis\u2014What does the evidence say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ljad162.038","DOI":"10.1093\/bjd\/ljad162.038","article-title":"418 A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): Baseline characteristics from the first 100 patients in Germany","volume":"188","author":"Kleinheinz","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/bjd\/ljad498.056","article-title":"Tralokinumab real world use in adults with atopic dermatitis: Baseline characteristics of the first 100 patients recruited to the TRACE study in the United States","volume":"190","author":"Armstrong","year":"2024","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:25Z","timestamp":1760034385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":25,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14165727"],"URL":"https:\/\/doi.org\/10.3390\/jcm14165727","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}